No abstract

1 E-6837 is a novel, selective and high-affinity 5-HT 6 receptor ligand (pK i : 9.13) which in vitro demonstrates partial agonism at a presumably silent rat 5-HT 6 receptor and full agonism at a constitutively active human 5-HT 6 receptor by monitoring the cAMP signaling pathway. 2 The effects of chronic treatment with E-6837 were determined in diet-induced obese (DIO)-rats on changes in body weight, food and water intake, plasma indices of comorbid risk factors, and weight regain on compound withdrawal. The centrally acting antiobesity drug, sibutramine, was used as the reference comparator. 3 Sustained body weight loss and decreased cumulative food intake of DIO-rats was observed with E-6837 (30 mg kg À1 , p.o., twice a day) during the 4-week treatment period. The onset of the E-6837 effect on body weight was slower than that of sibutramine (5 mg kg À1 , p.o.), while its maximal effect was greater, that is À15.7 versus À11.0%. 4 E-6837-induced weight loss was exclusively mediated by a decrease (31.7%) in fat mass, with a concomitant reduction (49.6%) in plasma leptin. Reduced obesity was also reflected in improved glycemic control. 5 Although weight regain occurred after withdrawal from either compound, the body weights after E-6837 (À6.6%) remained lower than after sibutramine (À3.8%) indicating that the greater efficacy of the former did not result in profound rebound hyperphagia/weight gain. 6 These results show that the 5-HT 6 receptor partial agonist, E-6837, is a promising new approach to the management of obesity with the potential to produce greater sustained weight loss than sibutramine.

Drug combination for the treatment of pain is common clinical practice. Co-crystal of Tramadol-Celecoxib (CTC) consists of two active pharmaceutical ingredients (APIs), namely the atypical opioid tramadol and the preferential cyclooxygenase-2 inhibitor celecoxib, at a 1:1 molecular ratio. In this study, a non-formulated 'raw' form of CTC administered in suspension (referred to as ctc) was compared with both tramadol and celecoxib alone in a rat plantar incision postoperative pain model. For comparison, the strong opioids morphine and oxycodone, and a tramadol plus acetaminophen combination at a molecular ratio of 1:17 were also tested. Isobolographic analyses showed that ctc exerted synergistic mechanical antiallodynic (experimental ED = 2.0 ± 0.5 mg/kg, i.p.; theoretical ED = 3.8 ± 0.4 mg/kg, i.p.) and thermal (experimental ED = 2.3 ± 0.5 mg/kg, i.p.; theoretical ED = 9.8 ± 0.8 mg/kg, i.p.) antihyperalgesic effects in the postoperative pain model. In contrast, the tramadol and acetaminophen combination showed antagonistic effects on both mechanical allodynia and thermal hyperalgesia. No synergies between tramadol and celecoxib on locomotor activity, motor coordination, ulceration potential and gastrointestinal transit were observed after the administration of ctc. Overall, rat efficacy and safety data revealed that ctc provided synergistic analgesic effects compared with each API alone, without enhancing adverse effects. Moreover, ctc showed similar efficacy but improved safety ratio (80, measured as gastrointestinal transit vs postoperative pain ED ratios) compared with the strong opioids morphine (2.5) and oxycodone (5.8). The overall in vivo profile of ctc supports the further investigation of CTC in the clinical management of moderate-to-severe acute pain as an alternative to strong opioids.

No abstract